| Display title | Chemistry:Tocilizumab |
| Default sort key | Tocilizumab |
| Page length (in bytes) | 39,850 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 323324 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>S.Timg |
| Date of page creation | 04:27, 6 February 2024 |
| Latest editor | imported>S.Timg |
| Date of latest edit | 04:27, 6 February 2024 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Tocilizumab, sold under the brand name Actemra among others, is an immunosuppressive drug, used for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, a severe form of arthritis in children, and COVID‑19. It is a humanized monoclonal antibody against the interleukin-6 receptor... |
